ID
16662
Beschrijving
Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis; ODM derived from: https://clinicaltrials.gov/show/NCT00027300
Link
https://clinicaltrials.gov/show/NCT00027300
Trefwoorden
Versies (1)
- 30-07-16 30-07-16 -
Geüploaded op
30 juli 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Multiple Sclerosis, Relapsing-Remitting NCT00027300
Eligibility Multiple Sclerosis, Relapsing-Remitting NCT00027300
- StudyEvent: Eligibility
Beschrijving
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Beschrijving
primary progressive, secondary progressive, or progressive relapsing ms.
Datatype
boolean
Alias
- UMLS CUI [1]
- C0751964
- UMLS CUI [2]
- C0751965
- UMLS CUI [3]
- C0393666
Beschrijving
ms relapse
Datatype
boolean
Alias
- UMLS CUI [1]
- C0856120
Beschrijving
communicable disease
Datatype
boolean
Alias
- UMLS CUI [1]
- C0009450
Beschrijving
abnormal laboratory results contraindicative for the administration of a recombinant humanized antibody
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C1254595
- UMLS CUI [1,2]
- C0522473
- UMLS CUI [1,3]
- C2985546
Beschrijving
drug hypersensitivity.
Datatype
boolean
Alias
- UMLS CUI [1]
- C0013182
Beschrijving
unable to perform the timed 25-foot walk, 9hpt, and pasat 3.
Datatype
boolean
Alias
- UMLS CUI [1]
- C3897356
Beschrijving
abnormal blood tests
Datatype
boolean
Alias
- UMLS CUI [1]
- C0854146
Similar models
Eligibility Multiple Sclerosis, Relapsing-Remitting NCT00027300
- StudyEvent: Eligibility
C0221198 (UMLS CUI [1,2])
C0751965 (UMLS CUI [2])
C0393666 (UMLS CUI [3])
C0522473 (UMLS CUI [1,2])
C2985546 (UMLS CUI [1,3])